R&D

Improving Generic Medicines Everyday

Leader in Research & Development

Year-in, year-out, we are amongst Canada’s Top 100 R&D investors, all domains confounded, according to the trusted, independent, Research Info Source survey, proving that a leading generic manufacturer can also be a major R&D contributor.

We are steadily investing in R&D in the areas of formulation of new generics, bioequivalence testing, and clinical research. All Pharmascience R&D is conducted in Canada and contributes significantly to pharmaceutical innovation.

Brian Des Islet, PhD Vice President & Chief Scientific Officer, Scientific Affairs

A Top 100 R&D Investor

Over the past 5 years,Research Info Source Inc. has consistently ranked Pharmascience on the list of Canada’s Top 100 Corporate R&D Investors, with R&D spending oscillating between 40 and 50 million $ per year. We, as a private, Canadian-owned company, have made it a strategic choice to invest all of our R&D in Canada.

Best-in-Class Scientific Expertise

We have a dedicated team of 115+ science experts with educational credentials ranging from PhD, MSc, BSc to technical diplomas. With backgrounds in organic and analytical chemistry, biology, medical sciences, biopharmaceutics, pharmacy, and engineering, our scientists are all devoted to the development of new generic pharmaceutical products for Canadian and global markets. Operating in formulation, technology transfer and project management teams, each member uses their specialized skills to achieve that goal.

Sharing our Expertise

The Pharmascience R&D team is also in demand throughout our industry by third parties who contract our expertise for the development of generic and innovative drug products.

Our integrated product development model includes:

  • Material characterization studies.
  • Formulation and process development using quality by design principles.
  • Analytical method development, troubleshooting, and validation.
  • Scale-up and technology transfer.
  • In vivo assessment of dosage form performance (pharmacokinetic studies).

State-of-the-Art Facilities

In our world-class labs, we have the unique capabilities to manage highly potent compounds.

 
We also have proven expertise in the development of high complexity products including novel drug delivery systems (modified and extended-release tablets, oral disintegrating tablets, mini-tablets, powders for reconstitution, and nanosuspensions) and innovative technologies (spray coating, lyophilization and media milling).

An important part of our R&D efforts is directed at filling the needs of underserviced populations such as young children or patients who could benefit from new, unapproved indications of generic drugs. At Pharmascience, we consider that patients deserve better and have pledged to develop such new product formulations or indications to fill the gap.

David Goodman, PhD President & Chief Executive Officer

Focusing on Underserviced Patient Populations

An important part of our R&D efforts is directed at filling the needs of underserviced populations such as young children or patients who could benefit from new, unapproved indications of generic drugs. Because of the combined effects of expired patent protection and generic pricing benchmarks, it is extremely difficult for manufacturers to invest in the development of new formulations, such as pediatric formulations, or in the development of new indications for genericized drugs, in a commercially viable manner.

We at Pharmascience consider that patients deserve better and have pledged to develop such new product formulations or indications to fill the gap. This will require working with government on policy amendments to make these new formulations or indications commercially viable.

Pharmascience regularly supports clinical or non-clinical animal studies with scientific and medical merit, developed and sponsored by independent investigators or academic sponsors.

Kent R.J. Major Vice President, Global Regulatory Affairs, Drug Safety, & Risk Management

Investigator Initiated Trials

Pharmascience regularly supports clinical or non-clinical animal studies with scientific and medical merit, developed and sponsored by independent investigators or academic sponsors. Our participation can take the form of either drug product and/or placebo supply, funding or in-kind assistance on regulatory applications.

If you are interested in conducting a clinical trial with any of Pharmascience’s marketed products, or are interested in a collaboration for a new clinical development proposal, contact us.

Looking for More Information?

Check out our FAQs for more information on R&D, biosimilar, bioequivalence, and generic drugs.

Frequently Asked Questions (FAQ)